Centene Swings to $2.19 EPS Profit, Raises FY26 View, Adds Board Shakeup
CNC has more than doubled off its 52-week low of $25.075.
Summary
Centene posted a sharp Q2 turnaround with GAAP EPS of $2.19 versus a $0.51 loss last year, driven by a much lower medical cost ratio. Revenue jumped to $53.6B from $48.7B. Full-year revenue guidance was hiked by $6B to $193.5B–$197.5B, and adjusted EPS is now seen above $4.80. The company also lifted its 2026 outlook as it contains medical costs. Separately, board member Kenneth Burdick is retiring and will be replaced by Paul Diaz, a managing partner at Cressey & Company, effective today. Shares are up 1.9% pre-market, reflecting the beat and raised outlook.
At the time of this announcement, CNC was trading at $65.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.6B. The 52-week trading range was $25.08 to $69.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.